Latest CRISPR Therapeutics News & Updates

See the latest news and media coverage for CRISPR Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

CRISPR Therapeutics

Gene-editing therapeutics developer

crisprtx.com

Headquarters: Boston, United States
Founded year: 2013
Company type: Public company
Number of employees: 300–500
Industry: Pharmaceuticals

Last updated Today

Latest news about CRISPR Therapeutics

In short: CRISPR Therapeutics secured expanded FDA approval for Casgevy in young children and reported strong revenue growth for the therapy.

Company announcements

July 2 CRISPR Therapeutics

CRISPR Therapeutics expands FDA approval for young children

It is the first gene-edited therapy approved for children this young, covering both sickle cell disease and beta thalassemia.

May 4 CRISPR Therapeutics

CRISPR Therapeutics reported Q1 2026 financial results and business update

Revenue included $43M from CASGEVY, cash increased to $2.44B, and development milestones advanced across pipeline.

March 10 CRISPR Therapeutics

CRISPR Therapeutics announces proposed $350M convertible senior notes offering

The notes due 2031 will be offered to qualified institutional buyers in a private offering.

February 12 CRISPR Therapeutics

CRISPR Therapeutics reports Q4 and full year 2025 financial results

CASGEVY generated $116M in 2025 revenue, with 64 patient infusions, and pipeline advances in autoimmune, oncology, and in vivo programs.

Media coverage

July 18 Yahoo Finance

Cathie Wood sells $11.7 million of tumbling semiconductor stock

Cathie Wood, head of Ark Investment Management, has built a reputation for backing artificial...

Never miss news about CRISPR Therapeutics

Track CRISPR Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

CRISPR Therapeutics competitors & trending companies

Browse news for competitors to CRISPR Therapeutics and other trending companies.